Combination Chemotherapy With or Without Bortezomib in Treating Patients With Classical Hodgkin Lymphoma That Has Returned or Does Not Respond to Prior Treatment.
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Bortezomib
Related studies linked through entity extraction aliases.
Bortezomib and Romidepsin in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1
Study of Bortezomib in Combination With Cyclophosphamide and Rituximab
- Status
- COMPLETED
- Phase
- PHASE2
Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2
Vorinostat and Bortezomib in Treating Patients With Advanced Soft Tissue Sarcoma
- Status
- COMPLETED
- Phase
- PHASE2
Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients
- Status
- COMPLETED
- Phase
- PHASE2
A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC)
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Study of Bendamustine Combined With Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
A Clinical Study to Assess the Safety and Activity of SRT501 Alone or in Combination With Bortezomib in Patients With Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE2
Desensitization in Kidney Transplantation
- Status
- COMPLETED
- Phase
- PHASE4
Treatment With Velcade (Bortezomib) Plus Dexamethasone (VD) or VD Plus Cyclophosphamide or VD Plus Lenalidomide in Patients With Multiple Myeloma Stabilized After 4 Cycles of VD
- Status
- COMPLETED
- Phase
- PHASE2
Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Study of Erlotinib in Combination With Bortezomib
- Status
- COMPLETED
- Phase
- PHASE1
Multiple Ascending Dose (MAD) Combination in Subjects With Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1
Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
SCH 727965 in Patients With Mantle Cell Lymphoma or B-Cell Chronic Lymphocytic Leukemia (Study P04715)
- Status
- TERMINATED
- Phase
- PHASE2
Bortezomib and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorders
- Status
- TERMINATED
- Phase
- PHASE2
Bortezomib and Gemcitabine in Treating Patients With Relapsed B-Cell Non-Hodgkin Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Phase I Study of MK-0683 in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-098)
- Status
- COMPLETED
- Phase
- PHASE1
Bortezomib, Doxorubicin Hydrochloride Liposome, and Rituximab in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to Treatment
- Status
- TERMINATED
- Phase
- PHASE2